Location Directory

Clinical trials in Cincinnati, Ohio

This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10564

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 50
States / cities: Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more

Conditions: Colorectal Adenocarcinoma
Interventions: Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Quality-of-Life Assessment, Questionnaire Administration; Drug · Dietary Supplement · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1027
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 676 more

Conditions: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions: Solriamfetol 150 MG, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Tucson, Arizona • Bellflower, California • Chino, California + 33 more

Conditions: Diaper Dermatitis
Interventions: Air Therapy; Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 30 Weeks to 1 Year
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 30 Years to 84 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more

Conditions: Rheumatic Heart Disease in Children
Interventions: CHW Delivered SAP Adherence Supports; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COVID-19
Interventions: CVXGA (CVXGA50), COMIRNATY®; Biological
Lead sponsor: CyanVac LLC; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 55
States / cities: Anniston, Alabama • Phoenix, Arizona • Chula Vista, California + 44 more

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Interventions: Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Months
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 193
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 101
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 77 more

Conditions: Asthma
Interventions: GP MDI, BFF MDI, Placebo MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Bakersfield, California • Lancaster, California • Long Beach, California + 12 more

Conditions: Bipolar Disorder I or II With a Major Depressive Episode
Interventions: ALTO-100, Placebo; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 48 more

Clinical trials in Cincinnati, Ohio

Filter and sort this location

Live official records

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Neonatal Intensive Care Unit (NICU) Diaper Dermatitis: Prevention and Treatment With Airtime

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

Adapting Enhanced Supports to Improve Patient Adherence to Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

ALTO-100 in Bipolar Disorder With Depression (BD-D)